• Z-LEHD-FMK: Precision Caspase-9 Inhibition in Apoptosis Rese

  2026-05-20

  Explore how Z-LEHD-FMK, a selective irreversible caspase-9 inhibitor, uniquely enables mechanistic dissection of mitochondrial apoptosis. This article delivers in-depth analysis for scientists seeking robust, translational apoptosis assay solutions.

• M344 Outperforms Vorinostat in Neuroblastoma HDAC Inhibition

  2026-05-20

  This study demonstrates that the novel HDAC inhibitor M344 exhibits stronger cytostatic, cytotoxic, and anti-migratory effects than vorinostat in neuroblastoma models. The findings highlight the potential of M344 for reducing tumor growth and improving therapeutic outcomes, supporting further preclinical development of HDAC inhibitors in pediatric oncology.

• 3X (DYKDDDDK) Peptide: Precision Epitope Tag for Protein Res

  2026-05-19

  The 3X (DYKDDDDK) Peptide enables high-sensitivity detection and reliable affinity purification of FLAG-tagged proteins. Its trivalent structure promotes robust antibody recognition and minimal interference with protein function. This article details evidence-based benchmarks, mechanism, and workflow integration for advanced recombinant protein studies.

• AR and ARv7 Targeting in TNBC: Enzalutamide’s Molecular Effe

  2026-05-19

  This study provides the first comprehensive evaluation of androgen receptor (AR) and its splice variant ARv7 as prognostic markers in triple-negative breast cancer (TNBC), demonstrating that their inhibition with Enzalutamide or EPI-001 suppresses key metastasis and EMT pathways. These findings clarify AR/ARv7’s role in TNBC progression and inform future research on targeted AR signaling modulation.

• Applied Workflows for EZ Cap™ Human PTEN mRNA (ψUTP) in Canc

  2026-05-18

  EZ Cap™ Human PTEN mRNA (ψUTP) enables robust, immune-evasive PTEN expression in mammalian systems, providing a decisive edge in PI3K/Akt pathway inhibition and drug resistance studies. This guide translates recent nanoparticle-mediated mRNA delivery breakthroughs into practical, stepwise protocols and troubleshooting insights for maximizing reproducibility and translational value.

• Genomic and Transcriptomic Instability Drives CRC Metastasis

  2026-05-18

  This study by Cho et al. systematically dissects how dynamic genomic and transcriptomic alterations during colorectal cancer metastasis shape therapeutic heterogeneity, using patient-derived xenograft models. The findings highlight the importance of subclonal evolution and pathway activation in influencing drug resistance, offering critical insights for future targeted therapy strategies.

• SGC-CBP30: Precision CREBBP/EP300 Bromodomain Inhibition in

  2026-05-17

  SGC-CBP30 stands out as a selective CREBBP/EP300 bromodomain inhibitor, enabling researchers to dissect transcriptional coactivator dependencies in cancer and epigenetic regulation. Its robust performance in workflows targeting super-enhancer hijacking and the TGF-β/SMAD3 pathway makes it an indispensable reagent for advanced cancer biology and lung adenocarcinoma research.

• Gallein and the Future of Gβγ Inhibition in Translational Me

  2026-05-16

  This thought-leadership article explores how Gallein, a G protein βγ subunit inhibitor from APExBIO, is redefining the landscape of GPCR-targeted translational research. Integrating mechanistic insights from recent discoveries in insulin-independent glucose uptake with preclinical data on cancer, immunology, and cardiometabolic disease, the article offers strategic guidance for translational researchers and highlights emerging opportunities for disease modeling and therapeutic innovation.

• Levofloxacin: Mechanistic Leverage in Multidomain Translatio

  2026-05-15

  Explore how Levofloxacin, a synthetic fluoroquinolone antibiotic, empowers translational researchers to bridge antibacterial, bone, and resistance biology. This thought-leadership article contextualizes recent resistance findings, mechanistic insights, and strategic workflow guidance, positioning APExBIO’s Levofloxacin as a robust platform for multidomain assay innovation.

• PCNA-POLD1 Targeting Halts Cardiomyocyte Hypertrophy via DNA

  2026-05-15

  Pal et al. unveil that pathological cardiac hypertrophy is driven by DNA synthesis through the PCNA-POLD1 axis, and that upregulation of p21 disrupts this process, reducing hypertrophic remodeling. The study highlights therapeutic potential in targeting DNA synthesis machinery to mitigate myocardial hypertrophy.

• γH2AX DNA Damage Detection Kit: Precision in DNA Damage Biom

  2026-05-14

  The γH2AX DNA Damage Detection Kit (Mouse mAb/Red) from APExBIO empowers researchers with robust, high-sensitivity visualization of DNA double-strand breaks. This article translates cutting-edge radiobiology and immunofluorescence advances into actionable workflows, troubleshooting strategies, and comparative insights for next-generation DNA damage and repair research.

• WP1066, JAK2/STAT3 Inhibitor: Applied Workflows and Innovati

  2026-05-14

  WP1066 stands out as a potent, cell-permeable JAK2/STAT3 inhibitor, empowering translational researchers in cancer and regenerative medicine. Explore how this tool enables advanced workflows—from cancer cell proliferation assays to bone defect repair—while leveraging the latest protocol insights and troubleshooting strategies.

• Cell Counting Kit-8 Plus: Sensitive Tetrazolium Salt Assays

  2026-05-13

  Cell Counting Kit-8 (CCK-8) Plus harnesses advanced WST-8 chemistry to elevate sensitivity and speed in cell proliferation and cytotoxicity assays. Its robust performance enables high-confidence viability quantification across diverse workflows, including challenging air–liquid interface models subjected to pollutant stress.

• MLN8237 (Alisertib): Strategic Aurora A Inhibition for Trans

  2026-05-13

  This thought-leadership article provides translational researchers with a mechanistic and strategic roadmap for harnessing MLN8237 (Alisertib), a potent, selective Aurora A kinase inhibitor, in cancer biology and advanced immunology workflows. By integrating new insights into Aurora A's role in trained immunity, recent mechanistic studies, and practical workflow guidance, this article advances beyond conventional product descriptions to empower innovative research and future-ready experimental design.

• Light-Inducible RNA-Releasing Proteins Enable Controlled Gen

  2026-05-12

  The referenced study introduces a rationally engineered light-inducible RNA-releasing protein (LIRP) that allows precise, reversible control of gene expression at the translational level in vivo. This optogenetic strategy advances the safety and flexibility of gene therapies, especially for chronic metabolic and retinal diseases requiring on-demand, tissue-specific intervention.

444 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page